Predicting High-Flow Nasal Cannula Failure in Acute Hypoxemic Respiratory Failure Using Metabolomics and Clinical Data

Metabolomics and Clinical Data to Predict High-Flow Nasal Cannula Failure and Optimize Respiratory Support in Acute Hypoxemic Respiratory Failure

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07607080

Acronym

META-RESPIRE

Enrollment

300

Registered

2026-05-26

Start date

2026-06-04

Completion date

2029-05-01

Last updated

2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Hypoxemic Respiratory Failure

Keywords

Acute Hypoxemic Respiratory Failure (AHRF), High-Flow Nasal Cannula (HFNC), Metabolomics, Respiratory Failure Prediction, Noninvasive Respiratory Support

Brief summary

The goal of this observational study is to determine whether metabolomic profiles combined with clinical data can predict high-flow nasal cannula (HFNC) failure and help optimize respiratory support in adult patients with acute hypoxemic respiratory failure (AHRF). The main questions it aims to answer are: Can metabolomic biomarkers identify patients at higher risk of HFNC failure? Does combining metabolomic and clinical data improve the prediction of respiratory support escalation and clinical outcomes? Participants will: Receive standard HFNC treatment according to clinical practice. Undergo collection of clinical, physiological, and laboratory data. Provide blood samples for metabolomic analysis during respiratory support.

Detailed description

This observational study aims to evaluate whether metabolomic signatures combined with routinely collected clinical and physiological data can improve the prediction of high-flow nasal cannula (HFNC) failure in patients with acute hypoxemic respiratory failure (AHRF). HFNC is widely used as first-line non-invasive respiratory support in AHRF; however, delayed recognition of treatment failure may lead to worse clinical outcomes, including delayed intubation and increased morbidity and mortality. The study will prospectively enroll adult patients with AHRF treated with HFNC. Clinical variables, respiratory parameters, laboratory results, and patient outcomes will be collected during routine clinical care. Blood samples will also be obtained for metabolomic analysis to identify molecular profiles associated with HFNC success or failure. The primary objective is to identify metabolomic and clinical predictors associated with HFNC failure and escalation of respiratory support. Secondary objectives include evaluating the association between metabolomic patterns and relevant clinical outcomes such as endotracheal intubation, duration of respiratory support, intensive care unit (ICU) length of stay, and mortality. The study also aims to develop predictive models integrating biological and clinical data to support personalized respiratory management strategies in AHRF.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients (≥18 years old). * Admission to the intensive care unit (ICU) with acute hypoxemic respiratory failure (AHRF). * Treatment with high-flow nasal cannula (HFNC) as the initial respiratory support strategy. * Inclusion within the first 24 hours after HFNC initiation. * Provision of informed consent by the patient or legally authorized representative.

Exclusion criteria

* Age \<18 years. * Active do-not-resuscitate (DNR) orders or limitation of therapeutic effort. * Refusal or inability to provide informed consent. * Previous invasive mechanical ventilation before study inclusion.

Design outcomes

Primary

Measure	Time frame	Description
HFNC Failure	Within the first 28 days after HFNC initiation.	Failure of high-flow nasal cannula (HFNC), defined as the need for invasive mechanical ventilation in patients with acute hypoxemic respiratory failure (AHRF).

Secondary

Measure	Time frame	Description
Predictive Performance of the Metabolomic-Clinical Model	Baseline and within the first 24 hours after HFNC initiation.	Comparison of the predictive accuracy of the metabolomic-clinical model versus the ROX index for predicting HFNC failure.

Countries

Spain

Contacts

CONTACTFrancisco José Parrilla-Gómez, MD, Phd

fparilla@hmar.cat+34 747424848

CONTACTJoan Ramon Masclans Enviz, MD, PhD

jrmasclans@hmar.cat+34 639383309

PRINCIPAL_INVESTIGATORFrancisco José Parrilla-Gómez, MD, Phd

Hospital del Mar

Outcome results